Showing results (2001-2010 of 2,138) with videos related to
Sort By:
Pageof 214
PNAS Nexus|January 24, 2025
Improving the solubility of pseudo-hydrophobic chemicals through co-crystal formulationIsis Janilkarn-Urena, Amanda Tse, Jieye Lin, et al.Lancet (London, England)|May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialPaul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.Journal of Visualized Experiments : Jove|December 14, 2011
Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-tomogram averagingJoel R Meyerson, Tommi A White, Donald Bliss, et al.Cancer Research|February 19, 2008
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavageSherif Daouti, Wen-hui Li, Hong Qian, et al.The British Journal of Psychiatry : the Journal of Mental Science|April 20, 2023
The effectiveness of a primary care-based collaborative care model to improve quality of life in people with severe mental illness: PARTNERS2 cluster randomised controlled trialRichard Byng, Siobhan Creanor, Benjamin Jones, et al.The Review of Scientific Instruments|April 4, 2023
Radiation, optical, power flow, and electrical diagnostics at the Z facility: Layout and techniques utilized to operate in the harsh environmentT J Webb, D E Bliss, G A Chandler, et al.Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.The Lancet. Oncology|August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialStephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH TrialIseult M Browne, Javier Pascual, Rosalind J Cutts, et al.The Lancet. Oncology|June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialDavid Cameron, James P Morden, Peter Canney, et al.Pageof 214